Growth hormone releasing factors
The existence of a human growth hormone-releasing hormone (GHRH) was demonstrated in 1964 by the ability of hypothalamic extracts to release growth hormone (GH) from pituitary tissue". Attempts at extracting and sequencing GHRH were unsuccessful until 1984when Ling and co-workers? isolated both a 44and a 40amino acid peptide from 1032human pituitary stalk-hypothalamic median eminences which had been preserved by freezing. The 44 amino acid peptide (GRF 1-44) was present in greater quantities than the 40 amino acid form (GRF 1-40) in this preparation (ratio 1.4to 1),although another preparation from 2050 acetone preserved pituitary-hypothalamic fragments had greater quantities of the 40 amino acid peptide (ratio 2.2 to 1). A third preparation of mixed acetone and frozen preserved fragments produced near equal proportions ofGRF 1-44 and GRF 1·40.It is therefore possible that acetone causes degradation of the 44 amino acid peptide. Whilst both peptides have similar potencies in vivo, the larger peptide has the greatest in vitro potency and it would appear logical to denote the 44amino acid peptide as human GHRH.
That these peptides are highly specific for GH release was already known, as they are identical to peptides which had been extracted from a human pancreatic tumour in 1982. This tumour had caused somatotroph hyperplasia and acromegaly", and had intrinsic GH-releasing properties attributable to its content of three peptides designated hp (human pancreatic) GRF 1-44, hpGRF 1-40 and hpGRF 1-37. A second pancreatic tumour studied at the same time contained hpGRF 1-40 alone". There is no international agreement on the nomenclature of these peptides, but if GHRH is defined as the 44 amino acid form, then the shorter peptides which act as GH-releasing factors can be abbreviated as GRFs, followed by numbers representing the number of amino acids present. The chemical structure of the shorter peptides is identical except for the number of amino acids that have been deleted. Further deletion of the carboxy-terminal amino acid residues produces peptides with progressively reduced in vitro bioactivity, though maximal GH release can be obtained down to GRF 1-21 as the dose-response curves remain parallel". De-amidation of the carboxy-terminal also reduces potency, and deletion or substitution of peptides at the amino terminal causes a profound, reduction in bioactivity". No analogue ofGHRH with 0141-0768/87/ 010003-02/$02.00/
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As expected, the greatest concentration of GHRH is found in the hypothalamus", with the majority in the cell bodies of the arcuate nucleus and in cell processes travelling to the median eminence for release of GHRH into hypothalamic-pituitary portal blood. However, in common with other neuropeptides, GHRH is found in small amounts in other parts of the central nervous system" as well as in the gastrointestinal tract and pancreas". The gut and not the hypothalamus is the most likely source of GHRH measured in the peripheral circulation!". Assay of GHRH in peripheral blood is therefore unlikely to provide any insight into the causation of acromegaly. Increased circulating concentrations will only be found in rare cases of ectopic production of GHRH 11. Similarly, experimental modification of circulating GHRH levels will not necessarily give any meaningful information on hypothalamic control mechanisms of GH secretion.
GHRH is remarkably specific for the release of GH and the only side effect observed so far is facial flushing following intravenous injection. GRFs have been used in combination with other hypothalamic releasing hormones as a test of pituitary function!", though interactions 13 may make these tests difficult to interpret. GHRH will give information on the presence of somatotrophs and their ability to secrete GH but will not decide whether the normal hypothalamic control of GH secretion is intact. For this we continue to rely on the stimuli of exercise, sleep and insulin-induced hypoglycaemia.
Many workers have now published data supporting the concept of idiopathic GH deficiency as a hypothalamic disorder of GHRH production or release. However, the GH response to GHRH in these subjects is highly variable and responsiveness may also vary with the duration of GHRH deficiency!", The largest study performed to date in apparently normal children with short stature demonstrates an overlap between these subjects and those with GH deficiency 1 s. In subjects with short stature secondary to delayed puberty and to emotional disturbance there is also overlap with the responses obtained in idiopathic GH deficiency!", These data suggest that the GH response to GRF will be of no value in predicting which subjects do and do not require therapy withGH.
Human GH therapy was withdrawn from the United Kingdom and the United States of America following the report of three neuropathologically confirmed cases of Creutzfeld-Jakob disease in patients who had been treated with human pituitary extracts 1 7 -19. Despite reassurances over the safety of GH extraction from human pituitaries20, it is unlikely that human GH will ever again be used in Western countries. It is therefore understandable that there is much current interest in the therapeutic use of GHRH. Selected patients with GH deficiency demonstrate an increase in growth velocity following treatment with nocturnal pulsatile subcutaneous administration of GRF1·40 2 1 • While this mimics the normal pattern ofGH secretion, it is possible that an adequate growth response may be achieved by less demanding regimens with once or twice daily administration of shorter (and therefore cheaper) GRF analogues 22 • The selection of patients, optimum size and timing of dose, and route of delivery will require prolonged and detailed study before GRF can be considered as a therapeutic agent. The biosynthetic GH produced by Kabivitrum has now been granted a product licence in the United Kingdom as an alternative to GH of human origin. Until direct comparisons are made between GHRH and biosynthetic GH, or the cost of GH becomes the major issue, practising clinicians will continue to use GH for therapy of GH deficiency in the immediate future 
